Olmesartan ameliorates hepatic insufficiency and serum TGF-β1 level in hypertensive patients with non-alcoholic fatty liver disease

Background：Because of westernization of lifestyle in recent years, the number of patients with lifestyle diseases, including obesity, metabolic syndrome, hypertension, dyslipidemia and diabetes mellitus, are increasing steadily. Recently, it has been noted that non‒alcoholic fatty liver disease（NAFLD）alone can cause liver cirrhosis or liver cancer. Angiotensin typeⅡ receptor blocker （ARB）is widely used in clinical practice as an antihypertensive...